{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:05Z","timestamp":1791932585020,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Millennium Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0501-4","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T13:37:45Z","timestamp":1499348265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study"],"prefix":"10.1186","volume":"10","author":[{"given":"Jian","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiequn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"issue":"11","key":"501_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"key":"501_CR2","volume-title":"SEER Cancer Statistics Review, 1975-2013","author":"N Howlader","year":"2016","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda: National Cancer Institute; 2016. Based on November 2015 SEER data submission (Posted to the SEER web site, April 2016). National Cancer Institute. Bethesda, MD. 21-9-2016."},{"issue":"6","key":"501_CR3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403.","journal-title":"Eur J Cancer"},{"issue":"7","key":"501_CR4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol. 2014;89(7):751\u20136.","journal-title":"Am J Hematol"},{"issue":"10015","key":"501_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(15)00551-6","volume":"387","author":"M Zhou","year":"2016","unstructured":"Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251\u201372.","journal-title":"Lancet"},{"issue":"1","key":"501_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1055-9965.243.14.1","volume":"14","author":"L Yang","year":"2005","unstructured":"Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14(1):243\u201350.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"501_CR7","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4:e239.","journal-title":"Blood Cancer J"},{"issue":"5","key":"501_CR8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138.","journal-title":"Leukemia"},{"issue":"10","key":"501_CR9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906\u201317.","journal-title":"N Engl J Med"},{"key":"501_CR10","doi-asserted-by":"crossref","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459\u201366.","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"501_CR11","unstructured":"Millennium Pharmaceuticals Inc. NINLARO\u00ae (ixazomib) capsules, for oral use. Prescribing information, November 2016. 2016. http:\/\/www.ninlaro.com\/downloads\/prescribing-information.pdf . Accessed 15 Dec 2016."},{"key":"501_CR12","unstructured":"Takeda Pharma A\/S. NINLARO\u00ae European Public Assessment Report - Product Information. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003844\/WC500217620.pdf . Accessed 15 Dec 2016."},{"issue":"17","key":"501_CR13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"key":"501_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-6-41","volume":"6","author":"J Hou","year":"2013","unstructured":"Hou J, Du X, Jin J, Cai Z, Chen F, Zhou DB, et al. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma: the MM-021 trial. J Hematol Oncol. 2013;6:41.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"501_CR15","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"18","key":"501_CR16","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"issue":"2","key":"501_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clml.2016.11.010","volume":"17","author":"A Agarwal","year":"2017","unstructured":"Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ. Practical considerations in managing relapsed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(2):69\u201377.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"501_CR18","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"14","key":"501_CR19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"501_CR20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"501_CR21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"12","key":"501_CR22","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777\u201384.","journal-title":"Blood"},{"issue":"Suppl","key":"501_CR23","first-page":"311","volume":"27","author":"AK Nooka","year":"2013","unstructured":"Nooka AK. Management of hematologic adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park). 2013;27(Suppl):311\u20138.","journal-title":"Oncology (Williston Park)"},{"key":"501_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-015-0198-1","volume":"8","author":"N Gupta","year":"2015","unstructured":"Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, et al. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed\/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015;8:103.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"501_CR25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma. Blood. 2014;124(7):1047\u201355.","journal-title":"Blood"},{"key":"501_CR26","doi-asserted-by":"publisher","unstructured":"Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling. Clin Pharmacokinet. 2017. [Epub ahead of print]. doi: 10.1007\/s40262-017-0526-4 .","DOI":"10.1007\/s40262-017-0526-4"},{"issue":"5","key":"501_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12542","volume":"79","author":"N Gupta","year":"2015","unstructured":"Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2015;79(5):789\u2013800.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"501_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9\u201354.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"14","key":"501_CR29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2217\/pgs.13.171","volume":"14","author":"C Ono","year":"2013","unstructured":"Ono C, Kikkawa H, Suzuki A, Suzuki M, Yamamoto Y, Ichikawa K, et al. Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. Pharmacogenomics. 2013;14(14):1745\u201364.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"501_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2015.70","volume":"16","author":"I Fricke-Galindo","year":"2016","unstructured":"Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado A, de Andr\u00e9s F, et al. Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113\u201323.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"501_CR31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/clpt.2012.221","volume":"94","author":"Y Tomita","year":"2013","unstructured":"Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther. 2013;94(1):37\u201351.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T14:35:22Z","timestamp":1659191722000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0501-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"article-number":"137"}}